Generics - Oncology, Markets & Marketing


Popular Filters

1 to 25 of 32 results

Intas reinforces cancer range with the first time launch of Azadine in India


Indian drugmaker Intas Pharmaceuticals says it has reinforced its oncology product range by successfully…

AzadineCelgeneGenericsIndiaIntas PharmaceuticalsMarkets & MarketingOncologyVidaza

Mylan launches generic Paraplatin Injection in USA

Mylan launches generic Paraplatin Injection in USA


US generics major Mylan has launched carboplatin injection, 50mg/5ml, in multi-dose vials, which is the…

Bristol-Myers SquibbGenericsMarkets & MarketingMylanOncologyParaplatinRegulationUSA

Hospira refutes high pricing of paclitaxel during drug shortage

Hospira refutes high pricing of paclitaxel during drug shortage


The Canadian subsidiary of USA-based injectable generic drugs specialist Hospira has refuted press reports…

CanadaGenericsHospiraMarkets & MarketingOncologyPaclitaxelPricing

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs


The local subsidiary of Israeli generics giant Teva Pharmaceutical Industries has launched Lonquex (lipegfilgrastim)…

AmgenBiosimilarsGenericsLonquexMarkets & MarketingNorthern EuropeOncologyTeva Pharmaceutical IndustriesUK

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India


US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

Teva updates on Lonquex and Granix launches

Teva updates on Lonquex and Granix launches


Israel-based Teva Pharmaceutical Industries announced two significant additions to its global oncology…

balugrastimBiosimilarsEuropeGenericsLonquexMarkets & MarketingNorth AmericaOncologyRegulationTeva Pharmaceutical Industries

Biocad enters deal for exporting rituximab biosimilar to Turkey


Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

Generic Temodar launches in USA


Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) and Perrigo (NYSE: PRGO;TASE) today…

GenericsMarkets & MarketingMerck & CoNorth AmericaOncologyPerrigoTemodarTeva Pharmaceutical Industries

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData


The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Sagent Pharma launches generic Zometa in USA; amends supply deal with Actavis


Privately-held US specialty pharmaceutical company Sagent Pharmaceuticals has announced the approval…

ActavisGenericsMarkets & MarketingNorth AmericaNovartisOncologyProductionSagent PharmaceuticalsZometa

Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts


Belgium drug developer Ablynx (Euronext Brussels: ABLX]) has entered into a research collaboration with…

AblynxGenericsidebenoneIdecortexLicensingMarkets & MarketingNeurologicalOncologyPharmaceuticalResearchSolent PharmaSpirogen

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021


Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021


While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Hospira re-launches generic Eloxatin in USA


US injectable drugs and infusion specialist Hospira (NYSE: HSP) last week announced the US re-launch…

GenericsMarkets & MarketingNorth AmericaOncology

Taiwan's ScinoPharm invests NT$1.1 billion in cytotoxic injectables facility


Taiwan based active pharmaceutical ingredients maker ScinoPharm (TWSE: 1789) says it plans to invest…

Asia-PacificFinancialGenericsMarkets & MarketingOncologyScinoPharm

Indonesian $16 million NSCLC drugs market kept afloat by high-priced branded drugs


Branded drugs for the treatment of non-small cell lung cancer (NSCLC) in Indonesia cost almost three…

Asia-PacificGenericsHealthcareMarkets & MarketingOncologyPharmaceutical

Merck KGaA collaborates with Dr Reddy's on biosimilars


With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

Prodigy Generics and eVenus launch injectable generic Camptosar in USA


Prodigy Generics, a division of Prodigy Health Supplier Corp (PHS), has launched injectable irinotecan,…

Camptosar InjectioneVenusGenericsirinotecanMarkets & MarketingNorth AmericaOncologyPfizerProdigy Generics

US FDA acts on cancer drugs shortages; move applauded by GPhA


The US Food and Drug Administration this week spelt out a series of steps to increase the supply of critically…

APP PharmaceuticalsDoxilGenericsHospiraMarkets & MarketingmethotrexateNorth AmericaOncologyPharmaceuticalRegulationSun Pharmaceutical Industries

Generic launches of irinotecan, Primaxin and Merrem


Japan’s ASKA Pharmaceuticals has announced the launch of irinotecan, the active ingredient of Campto…

ActavisAntibiotics and Infectious diseasesAPP PharmaceuticalsASKA PharmaceuticalsFresenius KabiGenericsirinotecanMarkets & MarketingMerrem I.V.Oncology

Amgen in cancer biosimilars deal with Watson


A collaboration has been entered into by Amgen (Nasdaq: AMGN), the world’s largest independent biotech…

AmgenBiotechnologyGenericsGlobalLicensingMarkets & MarketingOncologyWatson Pharmaceuticals

NSCL cancer drug market set to grow 2.5% a year between 2010 and 2020, despite generic erosion


Despite the arrival of generic competition – and ensuing sales erosion for several key agents used…

GenericsMarkets & MarketingOncologyPharmaceutical

1 to 25 of 32 results

Back to top